Implications of VIP and PACAP in Parkinson's Disease: What do we Know So Far?

被引:10
|
作者
Oliveira de Souza, Filipe Resende [1 ]
Ribeiro, Fabiola Mara [2 ]
d'Almeida Lima, Patricia Maria [1 ]
机构
[1] Univ Fed Sao Joao del Rei, Dept Nat Sci, Lab Immunol & Microbiol, Praca Dom Helvecio 74, BR-36301160 Sao Joao Del Rei, MG, Brazil
[2] Univ Fed Minas Gerais, Dept Biochem & Immunol, Lab Neurobiochem, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil
关键词
Vasoactive intestinal peptide (VIP); pituitary adenylate-cyclase activating polypeptide (PACAP); Parkinson's disease; neuroinflammation; oxidative stress; neuropeptides; neurodegenerative disease; VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; SH-SY5Y CELLS IMPLICATION; ADENYLATE-CYCLASE; TNF-ALPHA; T(H)17 CELLS; MOUSE MODEL; RECEPTOR; BRAIN; MICROGLIA;
D O I
10.2174/0929867327666200320162436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Parkinson's disease is one of the most common neurodegenerative disorders and although its aetiology is not yet fully understood, neuroinflammation has been identified as a key factor in the progression of the disease. Vasoactive intestinal peptide and pituitary adenylate-cyclase activating polypeptide are two neuropeptides that exhibit anti-inflammatory and neuroprotective properties, modulating the production of cytokines and chemokines and the behaviour of immune cells. However, the role of chemokines and cytokines modulated by the endogenous receptors of the peptides varies according to the stage of the disease. Methods: We present an overview of the relationship between some cytokines and chemokines with vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and their endogenous receptors in the context of Parkinson's disease neuroinflammation and oxidative stress, as well as the modulation of microglial cells by the peptides in this context. Results: The two peptides exhibit neuroprotective and anti-inflammatory properties in models of Parkinson's disease, as they ameliorate cognitive functions, decrease the level of neuroinflammation and promote dopaminergic neuronal survival. The peptides have been tested in a variety of in vivo and in vitro models of Parkinson's disease, demonstrating the potential for therapeutic application. Conclusion: More studies are needed to establish the clinical use of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide as safe candidates for treating Parkinson's disease, as the use of the peptides in different stages of the disease could produce different results concerning effectiveness.
引用
收藏
页码:1703 / 1715
页数:13
相关论文
共 50 条
  • [1] The immune system in Parkinson's disease: what we know so far
    Roodveldt, Cintia
    Bernardino, Liliana
    Oztop-Cakmak, Ozgur
    Dragic, Milorad
    Fladmark, Kari E.
    Ertan, Sibel
    Aktas, Busra
    Pita, Carlos
    Ciglar, Lucia
    Garraux, Gaetan
    Williams-Gray, Caroline
    Pacheco, Rodrigo
    Romero-Ramos, Marina
    BRAIN, 2024, 147 (10) : 3306 - 3324
  • [2] COVID-19 and Parkinson's Disease: What Do We Know So Far?
    Artusi, Carlo Alberto
    Romagnolo, Alberto
    Ledda, Claudia
    Zibetti, Maurizio
    Rizzone, Mario Giorgio
    Montanaro, Elisa
    Bozzali, Marco
    Lopiano, Leonardo
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 (02) : 445 - 454
  • [3] Dietary Restriction against Parkinson's Disease: What We Know So Far
    Wang, Zhonglei
    Cui, Yueran
    Wen, Lulu
    Yu, Haiyang
    Feng, Juan
    Yuan, Wei
    He, Xin
    NUTRIENTS, 2022, 14 (19)
  • [4] Vitamin E and Alzheimer's disease: what do we know so far?
    Browne, Declan
    McGuinness, Bernadette
    Woodside, Jayne, V
    McKay, Gareth J.
    CLINICAL INTERVENTIONS IN AGING, 2019, 14 : 1303 - 1317
  • [5] Mitochondrial Toxicant-Induced Neuronal Apoptosis in Parkinson's Disease: What We Know so Far
    Sivagurunathan, Narmadhaa
    Gnanasekaran, Priyadharshini
    Calivarathan, Latchoumycandane
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2023, 13 : 1 - 13
  • [6] What Do We Know about Theory of Mind Impairment in Parkinson's Disease?
    Trompeta, Clara
    Fernandez Rodriguez, Beatriz
    Gasca-Salas, Carmen
    BEHAVIORAL SCIENCES, 2021, 11 (10)
  • [7] Electronic cigarettes and cardiovascular health: what do we know so far?
    MacDonald, Andrea
    Middlekauff, Holly R.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 159 - 174
  • [8] Coconut oil: what do we really know about it so far?
    Lima, Renan da Silva
    Block, Jane Mara
    FOOD QUALITY AND SAFETY, 2019, 3 (02) : 61 - 72
  • [9] The effects of huntingtin-lowering: what do we know so far?
    Kaemmerer, William F.
    Grondin, Richard C.
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2019, 9 : 3 - 17
  • [10] Parkinson's disease: what the model systems have taught us so far
    Ghatak, Swagata
    Trudler, Dorit
    Dolatabadi, Nima
    Ambasudhan, Rajesh
    JOURNAL OF GENETICS, 2018, 97 (03) : 729 - 751